» Articles » PMID: 28573057

Cisplatin-Induced Renal Salt Wasting Requiring over 12 Liters of 3% Saline Replacement

Overview
Publisher Wiley
Specialty Nephrology
Date 2017 Jun 3
PMID 28573057
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cisplatin is known to induce Fanconi syndrome and renal salt wasting (RSW). RSW typically only requires transient normal saline (NS) support. We report a severe RSW case that required 12 liters of 3% saline. A 57-year-old woman with limited stage small cell cancer was admitted for cisplatin (80 mg/m) and etoposide (100 mg/m) therapy. Patient's serum sodium (SNa) decreased from 138 to 133 and 125 mEq/L within 24 and 48 hours of cisplatin therapy, respectively. A diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH) was initially made. Despite free water restriction, patient's SNa continued to decrease in association with acute onset of headaches, nausea, and dizziness. Three percent saline (3%S) infusion with rates up to 1400 mL/day was required to correct and maintain SNa at 135 mEq/L. Studies to evaluate Fanconi syndrome revealed hypophosphatemia and glucosuria in the absence of serum hyperglycemia. The natriuresis slowed down by 2.5 weeks, but 3%S support was continued for a total volume of 12 liters over 3.5 weeks. Attempts of questionable benefits to slow down glomerular filtration included the administration of ibuprofen and benazepril. To our knowledge, this is the most severe case of RSW ever reported with cisplatin.

Citing Articles

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.

Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T Int J Clin Oncol. 2023; 28(10):1259-1297.

PMID: 37382749 DOI: 10.1007/s10147-023-02372-4.


Profound hyponatremia and dehydration: A case of cisplatin induced renal salt wasting syndrome.

Bijoy George T, Kuriakose K, Chandrasekhara Pillai A, Powell T, Kleyman T Physiol Rep. 2023; 11(5):e15617.

PMID: 36868561 PMC: 9984271. DOI: 10.14814/phy2.15617.


Cisplatin Decreases ENaC Activity Contributing to Renal Salt Wasting Syndrome.

Soares A, Mironova E, Archer C, Contreras J, Stockand J, Abd El-Aziz T Cancers (Basel). 2020; 12(8).

PMID: 32752278 PMC: 7464492. DOI: 10.3390/cancers12082140.


Severe Hyponatremia Due to Cisplatin-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone.

Abid H, Siddiqui N, Gnanajothy R Cureus. 2019; 11(8):e5458.

PMID: 31641557 PMC: 6802817. DOI: 10.7759/cureus.5458.

References
1.
Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

2.
Lammers P, White L, Ettinger L . Cis-platinum-induced renal sodium wasting. Med Pediatr Oncol. 1984; 12(5):343-6. DOI: 10.1002/mpo.2950120509. View

3.
Oh G, Kim H, Shen A, Lee S, Khadka D, Pandit A . Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. Electrolyte Blood Press. 2015; 12(2):55-65. PMC: 4297704. DOI: 10.5049/EBP.2014.12.2.55. View

4.
Florea A, Busselberg D . Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2013; 3(1):1351-71. PMC: 3756417. DOI: 10.3390/cancers3011351. View

5.
Fulco R, Vannozzi M, Collecchi P, Merlo F, Parodi B, Civalleri D . Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia. Anticancer Res. 1990; 10(6):1603-10. View